Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 10/20 | 1.00 |
| ▸ | TRIM33 | Q9UPN9 | 10/20 | 1.00 |
| ▸ | BAZ2A | Q9UIF9 | 8/20 | 1.00 |
| ▸ | BRD9 | Q9H8M2 | 6/20 | 1.00 |
| ▸ | TRIM24 | O15164 | 1/20 | 1.00 |
| ▸ | TAF1L | Q8IZX4 | 1/20 | 1.00 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.60 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22339997 | 1.00 | BAZ2B (1.00) | BAZ2BTRIM33BAZ2ABRD9TRIM24 | |
| SCHEMBL24510745 | 0.85 | BAZ2B (1.00) | BAZ2BTRIM33BAZ2ABRD9TRIM24 | |
| SCHEMBL23318444 | 0.84 | BAZ2B (0.79) | BAZ2BTRIM33BAZ2ABRD9TRIM24 | |
| SCHEMBL29613447 | 0.79 | BAZ2B (0.77) | BAZ2BTRIM33BAZ2ABRD9TRIM24 | |
| SCHEMBL19586201 | 0.79 | BAZ2B (0.77) | BAZ2BTRIM33BAZ2ABRD9TRIM24 | |
| SCHEMBL20805428 | 0.77 | BAZ2B (0.61) | BAZ2BTRIM33BAZ2ABRD9TRIM24 | |
| SCHEMBL24510616 | 0.77 | BAZ2B (0.72) | BAZ2BTRIM33BAZ2ABRD9TRIM24 | |
| SCHEMBL22339804 | 0.76 | TRIM33 (0.61) | BAZ2BTRIM33BAZ2ABRD9TRIM24 | |
| SCHEMBL30427435 | 0.75 | BRD9 (1.00) | BAZ2BTRIM33BAZ2ABRD9TRIM24 | |
| SCHEMBL20805573 | 0.73 | BAZ2B (0.79) | BAZ2BTRIM33BAZ2ABRD9TRIM24 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025059442-A1 | MODULATING PLANT RESPONSES TO STRESS AND GROWTH WITH CHEMICALS | REMOTE EPIGENETICS INC. (US) | 2025-03-20 | — | — | WO | claimed |
| CN-116510024-A | Composition, preparation method and application thereof | 上海复东生物医药有限责任公司 | 2023-08-01 | — | — | CN | claimed |
| US-20230126711-A1 | ENTERIC NITRERGIC NEURONS AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-04-27 | — | — | US | claimed |
| EP-4125945-A1 | ENTERIC NITRERGIC NEURONS AND METHODS OF USING THE SAME | The Regents of the University of California (US) | 2023-02-08 | — | — | EP | claimed |
| CN-122097587-A | Application of BAZ2B gene in preparation of preparation for regulating and controlling viral myocarditis | — | 2026-05-29 | — | — | CN | disclosed |
| US-12630883-B2 | Test method of dividing blastic plasmacytoid dendritic cell neoplasm (BPDCN) into subtypes | JAPANESE FOUNDATION FOR CANCER RESEARCH (JP) | 2026-05-19 | — | — | US | disclosed |
| US-12533360-B2 | Inhibition of BRD proteins suppresses the phenotype of uterine fibroids | THE UNIVERSITY OF CHICAGO (US) | 2026-01-27 | — | — | US | disclosed |
| US-20250304585-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (COLDR) COMPOUNDS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2025-10-02 | — | — | US | disclosed |
| US-12427192-B2 | Water soluble adjuvant and composition containing same | Sumitomo Pharma Co., Ltd. (JP) | 2025-09-30 | — | — | US | disclosed |
| US-12383608-B2 | WT1 helper peptides and combinations of WT1 helper peptide and conjugate of cancer antigen peptides | Sumitomo Pharma Co., Ltd. (JP) | 2025-08-12 | — | — | US | disclosed |
| US-20250236844-A1 | STEM CELL DERIVED ISLET DIFFERENTIATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-07-24 | — | — | US | disclosed |
| US-20250163028-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2025-05-22 | — | — | US | disclosed |
| US-20220241409-A1 | WATER SOLUBLE ADJUVANT AND COMPOSITION CONTAINING SAME | Sumitomo Pharma Co., Ltd. (JP) | 2022-08-04 | — | — | US | disclosed |
| US-20220211844-A1 | WATER SOLUBLE ADJUVANT AND COMPOSITION CONTAINING SAME | Sumitomo Pharma Co., Ltd. (JP) | 2022-07-07 | — | — | US | disclosed |
| US-20220175714-A1 | USE OF RIVASTIGMINE IN PREPARATION OF ANTI-RADIATION MEDICAMENT | SOOCHOW UNIVERSITY (CN) | 2022-06-09 | — | — | US | disclosed |
| US-11331299-B2 | Medicinal use of serrulatane diterpenes | Kynan Duke IP, LLC (US) | 2022-05-17 | — | — | US | disclosed |
| US-20220117930-A2 | MEDICINAL USE OF SERRULATANE DITERPENES | THE UNIVERSITY OF SYDNEY (AU) | 2022-04-21 | — | — | US | disclosed |
| EP-3954382-A1 | WATER SOLUBLE ADJUVANT AND COMPOSITION CONTAINING SAME | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2022-02-16 | — | — | EP | disclosed |
| EP-3949983-A1 | WATER SOLUBLE ADJUVANT | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2022-02-09 | — | — | EP | disclosed |
| CN-113966326-A | Water soluble adjuvants | 大日本住友制药株式会社 | 2022-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12383608-B2 | WT1 helper peptides and combinations of WT1 helper peptide and conjugate of cancer antigen peptides | KLK3, TAP1, KLHL6 | BAZ2B 992/4885TRIM33 258/4885BAZ2A 1035/4885 |
| US-12630883-B2 | Test method of dividing blastic plasmacytoid dendritic cell neoplasm (BPDCN) into subtypes | BCL3, BRD4, BCL6 | BAZ2B 49/4885TRIM33 2447/4885BAZ2A 51/4885 |
| US-20220117930-A2 | MEDICINAL USE OF SERRULATANE DITERPENES | CYP11B1, CYP11B2, CYP51A1 | BAZ2B 4784/4885TRIM33 3001/4885BAZ2A 4795/4885 |
| US-20220241409-A1 | WATER SOLUBLE ADJUVANT AND COMPOSITION CONTAINING SAME | TP53, MYD88, AQP1 | BAZ2B 4609/4885TRIM33 1817/4885BAZ2A 4626/4885 |
| US-12427192-B2 | Water soluble adjuvant and composition containing same | TP53, MYD88, AQP1 | BAZ2B 4609/4885TRIM33 1817/4885BAZ2A 4626/4885 |
| US-20230126711-A1 | ENTERIC NITRERGIC NEURONS AND METHODS OF USING THE SAME | PROX1, MYH2, NOS2 | BAZ2B 4456/4885TRIM33 2181/4885BAZ2A 4473/4885 |
| US-20250304585-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (COLDR) COMPOUNDS | CASR, NPSR1, GSR | BAZ2B 1824/4885TRIM33 2220/4885BAZ2A 2459/4885 |
| US-11331299-B2 | Medicinal use of serrulatane diterpenes | CYP11B1, CYP11B2, CYP51A1 | BAZ2B 4784/4885TRIM33 3001/4885BAZ2A 4795/4885 |
| US-20250163028-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | UBQLN2, NEDD4, UBTF | BAZ2B 254/4885TRIM33 308/4885BAZ2A 120/4885 |
| US-20220211844-A1 | WATER SOLUBLE ADJUVANT AND COMPOSITION CONTAINING SAME | TP53, MYD88, AQP1 | BAZ2B 4609/4885TRIM33 1817/4885BAZ2A 4626/4885 |
| US-12533360-B2 | Inhibition of BRD proteins suppresses the phenotype of uterine fibroids | BRD2, BRDT, BRD1 | BAZ2B 17/4885TRIM33 2217/4885BAZ2A 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.